The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $59.4 Milhão dollars as of 22 May 2023. Advisors Capit owns over 869,565 units of Silverback Therapeutics stock worth over $59,402,968 and over the last 4 years Advisors sold SBTX stock worth over $0.
Advisors has made over 3 trades of the Silverback Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Advisors bought 869,565 units of SBTX stock worth $4,999,999 on 22 May 2023.
The largest trade Advisors's ever made was buying 1,236,800 units of Silverback Therapeutics stock on 25 September 2020 worth over $23,499,200. On average, Advisors trades about 824,211 units every 242 days since 2020. As of 22 May 2023 Advisors still owns at least 10,119,756 units of Silverback Therapeutics stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Over the last 6 years, insiders at Silverback Therapeutics have traded over $0 worth of Silverback Therapeutics stock and bought 2,785,936 units worth $58,491,063 . The most active insiders traders include Peter A. Thompson, Thilo Schroeder, eAdvisors Llc Orbi Med Capit.... On average, Silverback Therapeutics executives and independent directors trade stock every 60 days with the average trade being worth of $1,681,567. The most recent stock trade was executed by Laura Shawver on 5 August 2022, trading 78,740 units of SBTX stock currently worth $100,000.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics executives and other stock owners filed with the SEC include: